Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

– IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern

– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms

See more here